Literature DB >> 3145523

Enhanced pressor sensitivity to oral tyramine challenge following high dose selegiline treatment.

A Prasad1, V Glover, B L Goodwin, M Sandler, M Signy, S E Smith.   

Abstract

Blood pressure and heart rate responses to oral tyramine have been measured in healthy volunteers before and after administration of the selective monoamine oxidase B inhibitor selegiline at high dosage (30 mg/day). Treatment brought about a 2 to 4-fold increase in tyramine sensitivity and a concomitant small but significant reduction in plasma 4-hydroxy-3-methoxyphenylglycol concentration, pointing to the emergence of some degree of monoamine oxidase A inhibition. It is suggested that patients treated with selegiline 30 mg/day or more should be placed on a tyramine-free diet.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145523     DOI: 10.1007/bf00172970

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  TYRAMINE IN CHEESE RELATED TO HYPERTENSIVE CRISES AFTER MONOAMINE-OXIDASE INHIBITION.

Authors:  B BLACKWELL; L A MABBITT
Journal:  Lancet       Date:  1965-05-01       Impact factor: 79.321

2.  Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

Authors:  J Knoll; Z Ecseri; K Kelemen; J Nievel; B Knoll
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-05

3.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

4.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

Authors:  J P Johnston
Journal:  Biochem Pharmacol       Date:  1968-07       Impact factor: 5.858

5.  Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").

Authors:  E Varga; L Tringer
Journal:  Acta Med Acad Sci Hung       Date:  1967

6.  Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation.

Authors:  S Lipper; D L Murphy; S Slater; M S Buchsbaum
Journal:  Psychopharmacology (Berl)       Date:  1979-04-11       Impact factor: 4.530

7.  l-Deprenyl in atypical depressives.

Authors:  F M Quitkin; M R Liebowitz; J W Stewart; P J McGrath; W Harrison; J G Rabkin; J Markowitz; S O Davies
Journal:  Arch Gen Psychiatry       Date:  1984-08

8.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.

Authors:  D Pickar; R M Cohen; D C Jimerson; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Tyramine pressor sensitivity changes during deprenyl treatment.

Authors:  T Sunderland; E A Mueller; R M Cohen; D C Jimerson; D Pickar; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Dopamine oxidation and its inhibition by (-)-deprenyl in man.

Authors:  V Glover; J D Elsworth; M Sandler
Journal:  J Neural Transm Suppl       Date:  1980
View more
  4 in total

Review 1.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

2.  A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression.

Authors:  Larry Culpepper; Lawrence J Kovalick
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.

Authors:  P Bitsios; R W Langley; S Tavernor; K Pyykkö; M Scheinin; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

4.  Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Elena Shumay; Fred McCall-Perez; Millard Jayne; Gene-Jack Wang; David L Alexoff; Karen Apelskog-Torres; Barbara Hubbard; Pauline Carter; Payton King; Stanley Fahn; Michelle Gilmor; Frank Telang; Colleen Shea; Youwen Xu; Lisa Muench
Journal:  Neuropsychopharmacology       Date:  2014-09-24       Impact factor: 7.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.